The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 24, 2021
Filed:
Jun. 21, 2018
Applicant:
Celgene Corporation, Summit, NJ (US);
Inventors:
Ellen Filvaroff, San Francisco, CA (US);
Kristen M. Hege, Burlingame, CA (US);
Shaoyi Li, Warren, NJ (US);
Assignee:
Celgene Corporation, Summit, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4427 (2006.01); A61P 35/00 (2006.01); A61K 31/4985 (2006.01); A61K 31/44 (2006.01); A61K 31/517 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4985 (2013.01); A61K 31/44 (2013.01); A61K 31/517 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01);
Abstract
Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as 'Compound 1') to the patient having HCC characterized by HBV infection.